Screener
Arrowhead Research ARWR Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arrowhead Research in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Arrowhead Research’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000879407-26-000047
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 | Six Months Ended March 31, 2026 | Six Months Ended March 31, 2025 |
|---|---|---|---|---|
| Candidate costs | $99,449 | $71,191 | $204,439 | $148,087 |
| Discovery costs | 18,498 | 14,806 | 40,326 | 27,742 |
| Salaries | 33,546 | 26,907 | 63,585 | 54,052 |
| Facilities related | 7,595 | 6,737 | 15,697 | 14,487 |
| Total research and development expense, excluding non-cash expense | $159,088 | $119,641 | $324,047 | $244,368 |
| Stock compensation | 8,297 | 7,888 | 14,655 | 15,437 |
| Depreciation and amortization | 5,868 | 5,573 | 11,754 | 10,299 |
| Total research and development expense | $173,253 | $133,102 | $350,456 | $270,104 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Arrowhead Research's business segments — R&D?
- Arrowhead Research (ARWR) reported business segments — R&D of $173.25M in Q1 2026.
- How has Arrowhead Research's business segments — R&D changed year-over-year?
- Arrowhead Research's business segments — R&D increased by 30.2% year-over-year, from $133.1M to $173.25M.
- What does business segments — R&D mean?
- The total aggregate expense incurred for all research and development activities, including both cash and non-cash components. This represents the full financial commitment to discovering and developing new medical treatments. It is the primary indicator of the company's strategic focus on innovation.
Ask your AI about Arrowhead Research's business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude